NASDAQ:ALBO Albireo Pharma (ALBO) Stock Price, News & Analysis → Elon to Transform U.S. Economy? (From Porter & Company) (Ad) Free ALBO Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$43.99▼$44.9050-Day Range$43.50▼$44.9552-Week Range$16.02▼$45.23Volume1.24 million shsAverage Volume704,539 shsMarket Capitalization$913.91 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Albireo Pharma alerts: Email Address Ad Porter & CompanyElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. About Albireo Pharma Stock (NASDAQ:ALBO)Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA.Read More Ad Porter & CompanyElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. ALBO Stock News HeadlinesJanuary 19, 2024 | bizjournals.comProspect Park II in Fort LauderdaleOctober 1, 2023 | investing.comALBO Historical DataMay 5, 2024 | Porter & Company (Ad)Elon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.March 4, 2023 | finanznachrichten.deIpsen Pharma: Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolioFebruary 25, 2023 | seekingalpha.comALBO Albireo Pharma, Inc.February 18, 2023 | uk.finance.yahoo.comAlbireo Pharma, Inc. (ALBO)February 14, 2023 | marketwatch.comAlbireo Gets FDA Priority Review of Bylvay in Alagille Syndrome >ALBOFebruary 14, 2023 | finance.yahoo.comFDA Grants June 15, 2023 PDUFA Date to Albireo for Bylvay® in Alagille SyndromeMay 5, 2024 | Porter & Company (Ad)Elon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.January 24, 2023 | reuters.comALBO.PH - | Stock Price & Latest News | ReutersJanuary 21, 2023 | finance.yahoo.comWhy These Two Biotech Stocks Blasted Higher This WeekJanuary 11, 2023 | msn.comCowen & Co. Downgrades Albireo Pharma: Here's What You Need To KnowJanuary 11, 2023 | msn.comAnalysts move to downgrade Albireo Pharma after Ipsen's proposed acquisitionJanuary 11, 2023 | nasdaq.comAlbireo Pharma Spikes On Agreement To Be Acquired By IpsenJanuary 11, 2023 | markets.businessinsider.comExpert Ratings for Albireo PharmaJanuary 9, 2023 | benzinga.comShareholder Alert: Ademi LLP investigates whether Albireo Pharma, Inc. has obtained a Fair Price in its transaction with IpsenJanuary 9, 2023 | technews.tmcnet.comALBO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Albireo Pharma, Inc. Is Fair to ShareholdersJanuary 9, 2023 | finance.yahoo.comFrance-Based Ipsen Acquires Albireo Pharma Enriching Its Rare Disease Portfolio, PipelineJanuary 2, 2023 | seekingalpha.comAlbireo: Slowly Capturing Some Of The Liver Disease MarketDecember 21, 2022 | finance.yahoo.comWe're Not Very Worried About Albireo Pharma's (NASDAQ:ALBO) Cash Burn RateDecember 6, 2022 | finance.yahoo.comAlbireo Appoints Paul Streck, M.D., as Chief Medical Officer & Craig Hopkinson, M.D., to Board of DirectorsNovember 30, 2022 | finance.yahoo.comReimbursed Access to Bylvay® (odevixibat) Approved in France for Patients with PFIC 1 & 2November 10, 2022 | finance.yahoo.comAlbireo Pharma (NASDAQ:ALBO) dips 16% this week as increasing losses might not be inspiring confidence among its investorsNovember 9, 2022 | finance.yahoo.comAlbireo to Participate in Jefferies London Healthcare ConferenceNovember 9, 2022 | seekingalpha.comAlbireo Pharma, Inc. (ALBO) Q3 2022 Earnings Call TranscriptNovember 8, 2022 | finance.yahoo.comAlbireo Pharma (ALBO) Reports Q3 Loss, Tops Revenue EstimatesNovember 8, 2022 | finance.yahoo.comAlbireo Reports Q3 2022 Financial Results and Business UpdateSee More Headlines Receive ALBO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Albireo Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today5/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ALBO CUSIPN/A CIK1322505 Webwww.albireopharma.com Phone(857) 254-5555Fax203-796-5001Employees130Year Founded2003Profitability EPS (Most Recent Fiscal Year)($6.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-34,030,000.00 Net Margins-228.51% Pretax Margin-235.11% Return on Equity-97.13% Return on Assets-46.89% Debt Debt-to-Equity RatioN/A Current Ratio6.32 Quick Ratio6.23 Sales & Book Value Annual Sales$40.58 million Price / Sales22.52 Cash FlowN/A Price / Cash FlowN/A Book Value$9.11 per share Price / Book4.85Miscellaneous Outstanding Shares20,700,000Free Float19,273,000Market Cap$913.91 million OptionableOptionable Beta1.03 Social Links Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesRonald H. W. CooperPresident, Chief Executive Officer & DirectorSimon John HarfordChief Financial Officer & TreasurerJan Peter MattssonChief Scientific Officer, Managing Director-SwedenJoan ConnollyChief Technology OfficerPaul D. StreckChief Medical OfficerKey CompetitorsCentessa PharmaceuticalsNASDAQ:CNTAMacroGenicsNASDAQ:MGNXTyra BiosciencesNASDAQ:TYRAABIVAX Société AnonymeNASDAQ:ABVXCassava SciencesNASDAQ:SAVAView All Competitors ALBO Stock Analysis - Frequently Asked Questions How were Albireo Pharma's earnings last quarter? Albireo Pharma, Inc. (NASDAQ:ALBO) posted its earnings results on Thursday, November, 4th. The biopharmaceutical company reported $2.90 earnings per share for the quarter, beating the consensus estimate of ($0.38) by $3.28. The biopharmaceutical company earned $3.66 million during the quarter, compared to the consensus estimate of $22.33 million. Albireo Pharma had a negative trailing twelve-month return on equity of 97.13% and a negative net margin of 228.51%. During the same period in the previous year, the business earned ($1.96) EPS. What other stocks do shareholders of Albireo Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Albireo Pharma investors own include Energy Transfer (ET), Heat Biologics (HTBX), Amarin (AMRN), Exelixis (EXEL), Palatin Technologies (PTN), GW Pharmaceuticals (GWPH), Viking Therapeutics (VKTX), Agenus (AGEN), OPKO Health (OPK) and Pfizer (PFE). This page (NASDAQ:ALBO) was last updated on 5/5/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldThe asset beating inflation by 4xColonial MetalsUrgent Nvidia WarningAltimetryThe A.I. story nobody is telling you (Read ASAP)TradeSmithWarren Buffet Stockpiling Gold?Reagan Gold Group Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Albireo Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
